Asia Fresh News

Asia Fresh Stories

Archive for October 17th, 2011

Lab Dom Launches Its First Regenerative Medicine Educational Conference in Middle East

leave a comment »

Features seminars on the latest innovations in the field from leading UAE and European medical and scientific experts

BEIRUT, Lebanon, Oct. 13, 2011 /PRNewswire-Asia/ — Laboratoires Dom AVMM (Suisse) Inc., (Lab Dom) — a world-leading regenerative medicine and cellular therapy company — will hold its inaugural educational seminar for Middle East medical practitioners and aesthetic clinicians at the Four Season Hotel in Beirut, Lebanon on 14-15 October 2011.

The ‘1st Middle East Physician Educational Program on Swiss Cells Organotherapy and Stem Cell Therapy’ will be headlined by Switzerland’s Dr Olaf Kuhnke – President and Chairman of ZAEN, Europe’s largest academic organisation for the practice and control of complementary medicines — and will also feature the United Arab Emirate’s expert on precursor stem cell therapy treatments, Dr Dhafer Al-Gerrah.

“Given that world regenerative medicine revenues are expected to reach US$8.84bn by 2021 (Note), and that the Middle East expects to play a pivotal role in stem cell research and development, we believed the time was right to establish a key presence in this energetic and thought-leading market,” said Mike Chan, Co-founder, Laboratoires Dom AVMM (Suisse) Inc.

Presentations during the Lab Dom two-day educational training program in Beirut will be given by the company’s panel of international medical and scientific advisors, including; Dr Olaf Kuhnke (Switzerland); Dr Dhafer Al-Gerrah (UAE); Dr Rebekka Zirbel (Germany) and Claus-Peter Cremer (Germany). Successful case studies will focus on the use of Lab Dom’s precursor stem cell and organ-specific cell therapy products — MFIII of Switzerland and FCTI — for the treatment of chronic and degenerative diseases, as well as active-specific immunotherapy treatments for cancer.

Dr Dhafer Al-Gerrah from Abu Dhabi, UAE will present on the effective proven applications of precursor stem cell therapy for chronic aging, genetic, metabolic and chromosomal diseases using recent successful case studies in the treatment of autism and Down’s Syndrome.

“Lab Dom is currently poised to embark on an ambitious plan of global expansion, and we are hosting our first medical educational seminar in the Middle East specifically to open our doors for new preferred partners and associates to join us on our journey, share the bounty of our science and to grow with our new business,” stated Chan.

A well-respected pioneer at the forefront of the new era dawning in the global regenerative medicine and cellular therapy fields, Lab Dom is committed to continual evolution and change — both with the development of its cellular therapy products and as an organisation.

Lab Dom recently launched its dedicated ‘Change, with Lab Dom’ stakeholder campaign at the 7th European Masters in Aesthetic and Anti-Aging Medicine (EMAA 2011) exhibition, held in Paris, France in September this year. This campaign is aimed at servicing stakeholders and customers around the globe at a world’s best-practice level, and incorporates an innovative distribution model and a channel activation program.

“We are a family company, with family values, servicing a very human business. This is an unparalleled opportunity for partners to join us on our dynamic journey of expansion, and we invite interested practitioners and aesthetic clinicians in the Middle East to join us, and change with Lab Dom,” continued Chan.

Lab Dom’s exclusive Swiss Cellular Treatment programs held in Switzerland will also be a key feature introduced to the Middle East market during the two-day seminar program in Beirut. The company’s ‘Six Day, Six Star’ anti-aging and revitalisation program and the three-day ‘Executive Revitalisation Retreat’ are conducted at the MFIII / Orthobiomed Centre de Revitalisation in Roveredo, Switzerland and receive existing significant interest from the European and Chinese markets.

“With Switzerland, the traditional summer escape for many from the Middle East, we thought it is timely to introduce our Swiss cellular therapy treatment programs to the market and promote the opportunity to regenerate, revitalise and reinvigorate while holidaying in one of the most stunning and inspiring regions of the world,” said Michelle Wong, Co-founder, Laboratoires Dom AVMM (Suisse) Inc.

“We are in the business of providing the opportunity for change for humankind, and an opportunity to increase the quality of life itself.”

From 2012, Lab Dom will be introducing new levels of scientific and corporate governance, security, anti-fraud and counterfeit protection to take the industry lead on developments in the rapidly emerging regenerative medicine and cellular therapy fields.

The Beirut medical conference marks the second international event, in a series of six, that Lab Dom is participating in to create awareness of its new ‘Change, with Lab Dom’ stakeholder campaign, aimed at servicing stakeholders and customers around the globe at a world’s best-practice level which will be officially launched at a high-profile event in Las Vegas in December 2011.

About Lab Dom

Laboratoires Dom AVMM (Suisse) Inc., (Lab Dom) is a Swiss held and globally headquartered regenerative medicine and cellular therapy company, with regional Asia-Pacific headquarters in Kota Kinabalu, Malaysia.

Founded in 1998 by entrepreneurial husband and wife team, Mike Chan and Michelle Wong, Lab Dom is a world-leader in precursor stem cell, organ-specific cell, placental extracts and botanical cell product manufacturing and distribution, providing rejuvenation and revitalisation therapies to combat aging and chronic degenerative diseases.

With state-of-the-art laboratories and highly professional medical staff based in Switzerland, as well as the European Union and Asia-Pacific, Lab Dom is committed to innovative research and development in the rapidly expanding fields of regenerative medicine and anti-aging cellular therapy fields.

Lab Dom is currently embarking on a dynamic global expansion phase, aimed at increasing its presence in China, the European Union, the Middle East as well as the North and South American markets.

Note: Translational Regenerative Medicine: Market Prospects 2011-2021, published by visiongain, UK – July 2011

For media inquiries contact:

Andrew Tham
Message Manager
Lab Dom
Tel: +60-88-766266
Mobile: +60-16-8105490


SOURCE Laboratoires Dom AVMM (Suisse) Inc.

Written by asiafreshnews

October 17, 2011 at 3:27 pm

Posted in Uncategorized

Singapore MAS Preview: Is It Time to Join the Easing Club?

with one comment

Andrew Robinson, Market Analyst, Saxo Capital Markets

SINGAPORE, Oct. 13, 2011 /PRNewswire-Asia/ — The Monetary Authority of Singapore conducts its semi-annual review of monetary policy on Friday October 14th amid a gloomy external outlook and a stubbornly-high inflation rate. This suggests a finely-balanced argument for the next policy step and we take a look at the possible scenarios/responses and likely market reactions.

(Logo: )


On the economic front, the second quarter saw Singapore posting its first quarter-on-quarter negative growth since Q3 2010 as export markets in Europe and the US slowed. Following the -6.5% recorded in Q2, current surveys suggest that growth will rebound modestly in Q3 with median forecasts of +0.8% q/q growth (though the sample ranges from -7.1% to +7.7%.) though it would be easy for any undershoot to drag Singapore into a technical recession.

On the one hand, industrial production has shown some improvement on an annualized basis since hitting a cycle bottom in May, but PMI data, mirroring what we are seeing elsewhere in the globe, has been below the 50 threshold since July, and trending lower since April. Unemployment remains low, holding below 2.3% since end-2009 and registering 2.1% in Q2, a level that some feel is close to full-employment for the island state.

Inflation, the major issue for most Asian economies these past 2 years, remains stubbornly high and hit a cycle high of 5.7% y/y in August. The MAS’s core inflation, which excludes housing and transportation came in at 2.2% in Q2 and is expected to hold in the 2-3% range for the full year. The big debate is whether this is too high to prevent an MAS easing or can we regard it as still a temporary phenomenon?


1. No Change (10% chance) — maintains the SGD NEER trading band
at current levels, no re-centering and keeps the slow/gradual
appreciation of SGD (currently seen at +3% per annum) policy
in place.
2. Re-centre of band (10% chance) — brings the centre of the
SGD NEER trading band to current levels but maintains the
current SGD appreciation slope.
3. Slower Appreciation Path (30% chance) — Reduce the slope of
appreciation from the current 3% with no re-centering of the
trading band
4. Neutral Stance (50% chance) — Reduce slope of appreciation to
zero, possibly even combined with a re-centering of the SGD NEER
trading band.

Implications for the SGD

While the SGD NEER measures the SGD’s value against a basket of currencies, for illustration purposes we will adopt a USD-neutral stance and plot suggested reactions in USD/SGD.

(Photo: )

Scenario 1: Market’s least likely outcome will produce a kneejerk firmer SGD but 200-day MA just below 1.25 is expected to limit losses.

Scenario 2: Another kneejerk reaction higher for the SGD but not to the same extent as scenario 1 and likely confined to the 50% Fibonacci retracement of last large up-move, currently at 1.2600.

Scenario 3: A less-dovish outcome than is currently expected so SGD weakness will be limited at first but accelerating after a period of consolidation.

Scenario 4: Preferred outcome, SGD to trade on the weak side back to the recent high at 1.32.


Saxo Capital Markets Pte. Ltd. (“Saxo Capital Markets”) is licensed as a Capital Market Services provider and an Exempt Financial Advisor, and is supervised by the Monetary Authority of Singapore.

The author(s) and Saxo Capital Markets are not responsible for any loss arising from any investment based on any recommendation, forecast or any other information contained herein. The contents of this publication should not be construed as an express or implied promise, guarantee or implication by Saxo Capital Markets that clients will profit from the strategies herein or that losses in connection therewith can or will be limited. Trades in accordance with the recommendations in an analysis, especially in leveraged investments such as foreign exchange trading and investment in derivatives, can be very speculative and may result in losses as well as profits, in particular if the conditions mentioned in the analysis do not occur as anticipated.

You should carefully consider whether trading in leveraged products is appropriate for you in the light of your financial circumstances. You should be aware that dealing in products that are highly leveraged carry significantly greater risk than non-geared investments such as share trading. As such, you could both gain and lose large amounts of money. You may sustain losses in excess of the moneys you initially deposit and also in excess of the margin required to establish and maintain any positions in leveraged products.

For further information, please see:

About Saxo Capital Markets

Saxo Capital Markets Pte Ltd is a wholly-owned subsidiary of Saxo Bank A/S, the online trading and investment specialist. It serves as the Asia Pacific headquarters and holds a Capital Markets Services license from the Monetary Authority of Singapore. Saxo Capital Markets also holds a Commodity Broker licence from The International Enterprise Singapore.

Clients can trade Forex, CFDs, Stocks, Futures, Options and other derivatives via SaxoWebTrader and SaxoTrader, its leading multi-asset online trading platforms.

SaxoTrader is available directly through Saxo Capital Markets or through one of its institutional clients. White labelling is a significant business area for Saxo Capital Markets, and involves customising and branding of its online trading platform for other financial institutions and brokers.

Saxo Bank is headquartered in Copenhagen with regional offices in Singapore, Hong Kong, Milan, Madrid, London, Dubai, Amsterdam, Tokyo, Athens, Zurich, Prague and Paris. Saxo also operates representative offices in Sydney and Moscow.

Saxo’s position as an established FX house and its leading role in the foreign exchange market has been recognised by the industry’s leading reviews. In 2011, the Saxo Bank Group picked up six awards at the Euromoney annual FX survey for the following categories: Best Improved Overall Market Share by Volume ($10bn – $25bn) and ($5bn – $10bn), Best Speed of Execution, Best Research and Analytics, Best Effective Risk Management and Execution Strategies and Best Integrated Workflow and Compliance Solutions. Saxo Bank was also named “Best Forex Broker in Northern Europe” and “Best White Label Solution Provider” in the World Finance Foreign Exchange Awards 2011.

For more information, please visit

About Andrew Robinson, Market Analyst

Andrew Robinson has close to 30 years of experience in the financial markets and worked in key financial centers in London, Europe and Singapore. His expertise lies in FX, short-term interest rate products and precious metals.

Andrew joined Saxo Capital Markets in 2008 and currently writes a daily market commentary for the Asian FX trading session. He also contributes regularly to the Saxo Capital Markets’ blog ( and contributes articles with an Asia perspective to regional print media.

Andrew is a regular contributor on CNBC, Bloomberg and Thomson Reuters.

Media contacts:

Saxo Capital Markets Pte Ltd
Celeste Fong
Tel: +65 6303-7713

SOURCE﹛Saxo Capital Markets Pte Ltd

Written by asiafreshnews

October 17, 2011 at 12:46 pm

Posted in Uncategorized